How to buy C4 Therapeutics (CCCC) stock

C4 Therapeutics, Inc is an other business based in the US. C4 Therapeutics shares (CCCC) are listed on the NASDAQ and all prices are listed in US Dollars. C4 Therapeutics employs 99 staff and has a trailing 12-month revenue of around 0.00.

C4 Therapeutics stock price (NASDAQ: CCCC)

Use our graph to track the performance of CCCC stocks over time.

C4 Therapeutics shares at a glance

• Key figures

Information last updated 2021-07-23.

Latest market close	$36.95
52-week range	$19.00 - $48.98
50-day moving average	$38.99
200-day moving average	$37.89
Wall St. target price	$57.50
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	N/A

Buy C4 Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy C4 Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of C4 Therapeutics, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

C4 Therapeutics price performance over time

Historical closes compared with the close of $36.95 from 2021-05-28

1 week (2021-07-14)	N/A
1 month (2021-06-25)	-2.09%
3 months (2021-04-21)	N/A
6 months (2021-01-21)	N/A

1 year (2020-07-21)	N/A
2 years (2019-07-21)	N/A
3 years (2018-07-21)	N/A
5 years (2016-07-21)	N/A

C4 Therapeutics financials

Revenue TTM	$33.8 million
Gross profit TTM	$-44,273,000
Return on assets TTM	-13.89%
Return on equity TTM	-57.39%
Profit margin	-223.03%
Book value	$6.12
Market capitalisation	$1.9 billion

TTM: trailing 12 months

Shorting C4 Therapeutics shares

There are currently 2.8 million C4 Therapeutics shares held short by investors – that's known as C4 Therapeutics's "short interest". This figure is 18.5% up from 2.4 million last month.

There are a few different ways that this level of interest in shorting C4 Therapeutics shares can be evaluated.

C4 Therapeutics's "short interest ratio" (SIR)

C4 Therapeutics's "short interest ratio" (SIR) is the quantity of C4 Therapeutics shares currently shorted divided by the average quantity of C4 Therapeutics shares traded daily (recently around 723905.69948187). C4 Therapeutics's SIR currently stands at 3.86. In other words for every 100,000 C4 Therapeutics shares traded daily on the market, roughly 3860 shares are currently held short.

To gain some more context, you can compare C4 Therapeutics's short interest ratio against those of similar companies.

• Regeneron Pharmaceuticals (REGN.US): 1.71
• Biogen (BIIB.US): 0.53
• Alector (ALEC.US): 10.7

However C4 Therapeutics's short interest can also be evaluated against the total number of C4 Therapeutics shares, or, against the total number of tradable C4 Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case C4 Therapeutics's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 C4 Therapeutics shares in existence, roughly 60 shares are currently held short) or 0.0859% of the tradable shares (for every 100,000 tradable C4 Therapeutics shares, roughly 86 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against C4 Therapeutics.

Find out more about how you can short C4 Therapeutics stock.

C4 Therapeutics share dividends

We're not expecting C4 Therapeutics to pay a dividend over the next 12 months.

C4 Therapeutics overview

C4 Therapeutics, Inc. , a biopharmaceutical company, develops novel therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable degrader that is in preclinical stage targeting IKZF1/3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; and BRAF V600E to treat melanoma, non-small cell lung cancer, colorectal cancer, and other solid malignancies, as well as RET to treat lung cancer, sporadic medullary thyroid cancers, and other solid malignancies. C4 Therapeutics, Inc. has strategic collaborations with F. Hoffman-La Roche Ltd.

Frequently asked questions

What percentage of C4 Therapeutics is owned by insiders or institutions?
Currently 13.146% of C4 Therapeutics shares are held by insiders and 53.915% by institutions. How many people work for C4 Therapeutics?
Latest data suggests 99 work at C4 Therapeutics. When does the fiscal year end for C4 Therapeutics?
C4 Therapeutics's fiscal year ends in December. Where is C4 Therapeutics based?
C4 Therapeutics's address is: 490 Arsenal Way, Watertown, MA, United States, 02472 What is C4 Therapeutics's ISIN number?
C4 Therapeutics's international securities identification number is: US12529R1077